Deal overview
| Target | IONIS PHARMACEUTICALS INC (EPLONTERSEN IONIS-TTR-LRX) |
|---|---|
| Bidder | ASTRAZENECA PLC |
| Price | £50.00 Full version or £25.00 Light version |
| Publication Date | Dec 07, 2021 |
| Abstract | On 7 December 2021, the quoted UK pharmaceutical company AstraZeneca plc ("Astrazeneca") announced that it had into a commercialisation agreement with the quoted US pharmaceutical company Ionis Pharmaceutical Inc ("Ionis") for the ligand-conjugated antisense investigational medicine eplontersen, formerly known as IONIS-TTR-LRX ("Eplontersen"). Upfront consideration amounted ... |
| Number of pages (Full version) | 5 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2024 M&A Monitor Limited
